Abstract
Dolutegravir (Tivicay—ViiV Healthcare), the second integrase strand transfer inhibitor (INSTI) for treating HIV-1 infection, has received FDA approval. Dolutegravir blocks HIV replication by preventing viral DNA from integrating into the genetic material of immune cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
